UK pharmaceutical group GSK is in talks to acquire oncology biotech Nuvalent for more than $9 billion, in what would be the British drugmaker's largest acquisition in more than a decade, the Financial Times reported Tuesday. The companies have been in discussions with the aim of finalizing a deal as early as this week, the FT reported, citing people familiar with the matter. Representatives for GSK and Nuvalent did not respond to CNBC's requests for comment. Both sides have yet to reach a final

Tag-uri: GSK